Valopicitabine | 640281-90-9

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: Valopicitabine
• 英文别名: [(2R,3R,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-4-hydroxy-2-(hydroxymethyl)-4-methyloxolan-3-yl] (2S)-2-amino-3-methylbutanoate
• CAS: 640281-90-9
• 化学式: C₁₅H₂₄N₄O₆
• 分子量: 356.37
• InChiKey: TVRCRTJYMVTEFS-ICGCPXGVSA-N

物化性质

• 沸点：
  548.4±60.0 °C(Predicted)
• 密度：
  1.54±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -2
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  161
• 氢给体数：
  4
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  [(2R,3R,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-4-hydroxy-2-(hydroxymethyl)-4-methyloxolan-3-yl] 3-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoate 以81的产率得到Valopicitabine
  参考文献：
  名称：

  J. Med. Chem. 2006, 49, 6614-6620

  摘要：

  DOI：

文献信息

• COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES
  申请人：Johansen Lisa M.

  公开号：US20100009970A1

  公开（公告）日：2010-01-14

  The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E) and the agent or combination of agents includes sertraline, a sertraline analog, UK-416244, or a UK-416244 analog. Also featured are screening methods for identification of novel compounds that may be used to treat a viral disease.

  本发明涉及用于治疗病毒性疾病的组合物、方法和试剂盒。在某些实施方式中，病毒性疾病是由单链RNA病毒、黄病毒科病毒或肝病毒引起的。在特定实施方式中，病毒性疾病是病毒性肝炎（例如甲型肝炎、乙型肝炎、丙型肝炎、丁型肝炎、戊型肝炎），药剂或药剂组合包括舍曲林、舍曲林类似物、UK-416244或UK-416244类似物。还包括用于鉴定可用于治疗病毒性疾病的新化合物的筛选方法。
• 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
  申请人：——

  公开号：US20040077587A1

  公开（公告）日：2004-04-22

  The 3′-L-valine ester of &bgr;-D-2′-C-methyl-ribofuranosyl cytidine provides superior results against flaviviruses and pestiviruses, including hepatitis C virus. Based on this discovery, compounds, compositions, methods and uses are provided for the treatment of flaviviridae, including HCV, that include the administration of an effective amount of val-mCyd or its salt, ester, prodrug or derivative, optionally in a pharmaceutically acceptable carrier. In an alternative embodiment, val-mCyd is used to treat any virus that replicates through an RNA-dependent RNA polymerase.

  &bgr;-D-2′-C-甲基核糖苷鸟苷的3'-L-缬氨酸酯提供了对黄病毒和猪瘟病毒（包括丙型肝炎病毒）更好的结果。基于这一发现，提供了用于治疗黄病毒科（包括HCV）的化合物、组合物、方法和用途，其中包括在药学上可接受的载体中投与有效量的缬氨酸酯-mCyd或其盐、酯、前药或衍生物。在另一种实施方式中，缬氨酸酯-mCyd被用于治疗任何通过RNA依赖性RNA聚合酶复制的病毒。
• Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections
  申请人：SOMMADOSSI Jean-Pierre

  公开号：US20090238790A2

  公开（公告）日：2009-09-24

  Provided herein are compounds, compositions and methods for the treatment of liver disorder, including HCV and/or HBV infections. Specifically, compound and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.

  本文提供了用于治疗肝脏疾病，包括HCV和/或HBV感染的化合物、组合物和方法。具体来说，披露了核苷衍生物的化合物和组合物，可以单独或与其他抗病毒药物联合使用。
• Fluorinated Pyrrolo[2,3-D]Pyrimidine Nucleosides for the Treatment of Rna-Dependent Rna Viral Infection
  申请人：MacCoss Malcolm

  公开号：US20080280842A1

  公开（公告）日：2008-11-13

  The present invention provides fluorinated pyrrolo[2,3,d]pyrimidine nucleoside compounds which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as precursors to inhibitors of hepatitis C virus (HCV) NS5B polymerase, as precursors to inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such fluorinated pyrrolo[2,3-d]pyrimidine nucleoside alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the fluorinated pyrrolo[2,3-d]pyrimidine nucleoside of the present invention.

  本发明提供了一种氟代吡咯并[2,3,d]嘧啶核苷化合物，其是RNA依赖性RNA病毒聚合酶的抑制剂。这些化合物是RNA依赖性RNA病毒复制的抑制剂，可用于治疗RNA依赖性RNA病毒感染。它们特别适用于作为丙型肝炎病毒（HCV）NS5B聚合酶抑制剂的前体，作为HCV复制抑制剂的前体，和/或用于治疗丙型肝炎感染。该发明还描述了含有这种氟代吡咯并[2,3-d]嘧啶核苷单独或与其他对RNA依赖性RNA病毒感染，特别是HCV感染活性的药物组合物。还公开了使用本发明的氟代吡咯并[2,3-d]嘧啶核苷抑制RNA依赖性RNA聚合酶，抑制RNA依赖性RNA病毒复制和/或治疗RNA依赖性RNA病毒感染的方法。
• Compounds and pharmaceutical compositions for the treatment of viral infections
  申请人：Sommadossi Jean-Pierre

  公开号：US20080286230A1

  公开（公告）日：2008-11-20

  Provided herein are compounds, compositions and methods for the treatment of liver disorder, including HCV and/or HBV infections. Specifically, compound and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.

  本文提供了用于治疗肝脏疾病，包括HCV和/或HBV感染的化合物、组合物和方法。具体地，本文公开了核苷衍生物的化合物和组合物，可以单独或与其他抗病毒药物联合使用。